Testing a new drug to relieve pain from endometriosis
Official title: Validating SER-014, a TRPV1 antagonist, to treat endometriosis
Funded at Serentrix, LLC · NIH-10916997 · Data updated 2026-11-12
This study is testing a new drug called SER-014 to see if it can help relieve pain from endometriosis without the risks of addiction, offering a safer option for women who struggle with this condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Serentrix, LLC NIH-funded |
| Lab location | 1 site (Exton, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $384,418 |
| NIH project number | 1R41HD115418-01 |
| Project ID | NIH-10916997 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are women diagnosed with endometriosis who experience chronic pain and have not found relief from existing treatments.
✕Less likely to help
Patients who do not have endometriosis or those whose pain is not related to this condition may not benefit from this research.
What this research studies
This research focuses on validating SER-014, a drug that blocks the TRPV1 receptor, which is involved in pain and inflammation associated with endometriosis. Endometriosis is a painful condition affecting many women, and current treatments often fall short, leading to reliance on opioids. By targeting the TRPV1 receptor, SER-014 aims to provide a non-addictive alternative for pain relief. The study will involve assessing the drug's effectiveness and safety in patients suffering from this condition.
Why it matters
Potential benefit: If successful, this research could offer a new, non-addictive treatment option for women suffering from endometriosis-related pain.
How similar studies have gone: Other research has shown promise in targeting TRPV1 for pain management, suggesting that this approach could be effective.
Where this research is happening
-
Serentrix, LLC
Exton, United States Active
Researchers
- Principal investigator: Bhargava, Kumaril — Serentrix, LLC
- Study coordinator: Bhargava, Kumaril
Related research
Other NIH-funded projects on the same topics.
-
Molecular clues to endometriosis-related infertility
This grant explores how molecular changes in endometriosis contribute to infertility, with the aim of finding better ways to diagnose and treat the condition.
-
Hormonal Influences on Inflammation in Endometriosis
A study in adult women with endometriosis looks at how hormones and immune pathways interact to influence inflammation and symptoms.
-
How genes influence endometriosis in women of different racial and ethnic backgrounds
The team will compare genetic changes in tissue from women of various races who have endometriosis to find molecular targets for better treatments.
-
Quantum diamond sensor endoscopy to map iron in endometriosis
A tiny quantum sensor built into an endoscope will map iron in endometriosis lesions to help diagnose the disease noninvasively.
-
Understanding how RPLP1 affects endometriosis and adenomyosis
A patient-focused look at how a ribosomal protein called RPLP1 may drive tissue changes in endometriosis and adenomyosis and what this could mean for future therapies.
-
CXCR4 methylation in endometriosis and its role as an early biomarker and non-hormonal therapy target
This project explores how changes in CXCR4 gene regulation may help diagnose endometriosis earlier and point toward non-hormonal treatments for the condition.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.